%0 Generic %C [S.l.] : %D 2018. %I Canadian Agency for Drugs and Technologies in Health, %T Clinical Review Report Nitisinone (Orfadin): (Sobi Canada Inc.): Indication: For the treatment of patients with hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine. %U http://SK8ES4MC2L.search.serialssolutions.com/?sid=sersol&SS_jc=TC_035307897&title=Clinical%20Review%20Report%3A%20Nitisinone%20%28Orfadin%29%3A%20%28Sobi%20Canada%20Inc.%29%3A%20Indication%3A%20For%20the%20treatment%20of%20patients%20with%20hereditary%20tyrosinemia%20type%201%20in%20combination%20with%20dietary%20restriction%20of%20tyrosine%20and%20phenylalanine